]> 2026-04-12T04:08:39-07:00 Anti-CMV Dendritic Cell Vaccine 0 en Dendritic cell vaccines like this one are known for their favorable safety profile, with predominantly mild, manageable adverse effects. 2025-01-18T08:28:12Z 2460693.8529167 Anti-CMV Dendritic Cell Vaccine 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","This approach relies on the finding that most GBM tumors are infected with the\ncytomegalovirus, a common herpes virus. GBMs have a high incidence of the virus being\npresent (by some estimates over 90%) whereas normal brain cells do not. The new\ntreatment approach involves targeting a specific protein component of the CMV virus,\nwhich then kills the virus and the cell harboring it.\n\nResults of a small trial for Duke\u2019s anti-CMV dendritic cell vaccine with or without\npreconditioning with an injection of tetanus\/diptheria toxoid was published in Nature in\nMarch 2015 (320). There were 6 newly diagnosed glioblastoma patients in each arm. In\nthe 6 patients treated with the vaccine but without tetanus\/diptheria preconditioning,\nmedian progression-free and overall survival freom diagnosis was 10.8 and 18.5, not\nsignificantly better than historical controls. In the group of patients receiving\npreconditioning of the injection site with tetanus\/diptheria, three of the patients were\nalive without disease progression at 44-47 months from diagnosis. A Wall Street Journal\narticle published at the same time as the Nature study gave more up-to-date information,\nrevealing that two of these longer-term survivors had died at nearly 5 and 6 years from\ndiagnosis, while the remaining patient was still alive over 8 years from diagnosis. An\nupdate from the 2016 AANS conference revealed that this patient was still alive without\ntumor regrowth at 120 months (10 years). The purpose of the tetanus\/diptheria booster is\nto improve migration of the dendritic cells to lymph nodes. Despite the striking success of\nthe anti-CMV dendritic cell vaccine combined with a tetanus\/diptheria booster injection,\na randomized phase 2 trial is scheduled to open in 2015 with one arm randomized to\nreceive the tetanus\/diptheria toxoid preconditioning, and the other arm randomized to\n\nreceive saline (essentially placebo). Both arms receive the anti-CMV dendritic cell vaccine\n(trial NCT02366728).\n\nA second single-arm phase II trial (ATTAC-GM) combined dose-intense temozolomide\n(100 mg\/mz2 for 21 days of a 28 day cycle) with anti-CMV dendritic cell vaccine and\ntetanus preconditioning. Median progression-free and overall survival for the 11 patients\nwas a remarkable 25.3 and 41.1 months. This data was presented at the 2016 annual\nAANS meeting by Kristen Batich.\n\nA separate trial (NCT00626483) at Duke for newly diagnosed glioblastoma is testing the\nCMV-targeted dendritic cell vaccine in combination with basiliximab, a CD25 antibody\nintended to inhibit the regulatory T-cell (Treg) population. In an abstract published for\nthe ASCO 2015 meeting, we can read that in a pilot study of seven patients treated with\nthis combination therapy, median progression-free and overall survival was an impressive\n23.5 and 30.3 months respectively.\n\nCurrently recruiting clinical trials testing CMV pp65 vaccines with or without\ntetanus\/diptheria preconditioning or basiliximab include the ELEVATE trial at Duke\nUniversity (NCT02366728), the PERFORMANCE trial also at Duke (NCT02864368), the\nATTAC-II trial at the University of Florida (NCT02465268), and the AVERT trial for\nrecurrent grade III glioma and GBM at Duke University (NCT02529072)."] Anti-CMV Dendritic Cell Vaccine# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name